Taking the question as asked, rather than the general version of it. The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study. A curve that has not flattened is a real finding, but it also means the true plateau is unknown, and phase 2 populations are small and selected.

LabKate said:

The phase 2 numbers were about 24% mean weight loss at 48 weeks on the top dose, with the curve still descending at the end of the study.

Fair, but phase 2 tolerability figures rarely survive contact with phase 3 scale. Triple agonism means three receptor systems generating adverse events, and the dropout column is the one I would read first when the larger trials report.

DerekSJ_a1c said:

Triglycerides dropped by half, HDL barely moved, and my calculated LDL is almost exactly where it started, which is not the outcome I had been…

Same experience, arrived at from the opposite direction.

From the other side of the consultation, briefly.

Before/after bloodwork compilation for the lipid panel — everything in one place for those who want comprehensive data:

Every single metabolic marker improved. This is why I'm a believer in this therapy.